Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349

被引：41

作者：

Pei, Zhonghua ^{[1
]}

Blackwood, Elizabeth ^{[2
]}

Liu, Lichuan ^{[3
]}

Malek, Shiva ^{[4
]}

Belvin, Marcia ^{[2
]}

Koehler, Michael F. T. ^{[1
]}

Ortwine, Daniel F. ^{[1
]}

Chen, Huifen ^{[1
]}

Cohen, Frederick ^{[1
]}

Kenny, Jane R. ^{[3
]}

Bergeron, Philippe ^{[1
]}

Lau, Kevin ^{[1
]}

Ly, Cuong ^{[1
]}

Zhao, Xianrui ^{[1
]}

Estrada, Anthony A. ^{[1
]}

Tom Truong ^{[2
]}

Epler, Jennifer A. ^{[2
]}

Nonomiya, Jim ^{[4
]}

Lan Trinh ^{[4
]}

Sideris, Steve ^{[4
]}

Lesnick, John ^{[4
]}

Bao, Linda ^{[5
]}

Vijapurkar, Ulka ^{[2
]}

Mukadam, Sophie ^{[3
]}

Tay, Suzanne ^{[3
]}

Deshmukh, Gauri ^{[3
]}

Chen, Yung-Hsiang ^{[3
]}

Ding, Xiao ^{[3
]}

Friedman, Lori S. ^{[2
]}

Lyssikatos, Joseph P. ^{[1
]}

机构：

[1] Genentech Inc, Dept Discovery Chem, San Francisco, CA 94080 USA

[2] Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA

[3] Genentech Inc, Dept DMPK, San Francisco, CA 94080 USA

[4] Genentech Inc, Dept Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA

[5] Genentech Inc, Dept Pharmaceut, San Francisco, CA 94080 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2013年 / 4卷 / 01期

关键词：

Mammalian target of rapamycin; mTOR; TDI; urea bioisostere; MECHANISM-BASED INACTIVATION; CYTOCHROME-P450; ENZYMES; GDC-0941; CANCER; KINASE;

D O I：

10.1021/ml3003132

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Aberrant activation of the PI3K-Akt-mTOR signaling pathway has been observed in human tumors and tumor cell lines, indicating that these protein kinases may be attractive therapeutic targets for treating cancer. Optimization of advanced lead 1 culminated in the discovery of clinical development candidate 8h, GDC-0349, a potent and selective ATP-competitive inhibitor of mTOR GDC-0349 demonstrates pathway modulation and dose-dependent efficacy in mouse xenograft cancer models.

引用

页码：103 / 107

页数：5

共 50 条

[1] mTOR通路抑制剂GDC-0349对CCRF-CEM细胞增殖和凋亡的影响
李川
胡荣
刘卓刚
现代肿瘤医学, 2019, 27 (16) : 2803 - 2806
[2] Discovery of GDC-0853: A potent & selective BTK inhibitor for the treatment of lupus & rheumatoid arthritis
Young, Wendy
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
[3] Discovery of GDC-0853: A highly potent, selective, and non-covalent Btk inhibitor
Young, Wendy
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
[4] Discovery of GDC-0980, a selective PI3K/mTOR inhibitor in clinical trials
Sutherlin, Daniel P.
Belvin, Marcia
Bao, Linda
Berry, Leanne
Berry, Megan
Castanedo, Georgette
Edgar, Kyle
Folkes, Adrian
Friedman, Lori
Heffron, Tim
Patel, Sonal
Olivero, Alan
Lesnick, John
Lewis, Cristina
Marsters, James
Nonomiya, Jim
Pang, Jodie
Prior, Wei Wei
Salphati, Laurent
Sampath, Deepak
Tsui, Vickie
Wallin, Jeff
Wei, BinQing
Weismann, Christian
Zhu, Bing-Yan
CANCER RESEARCH, 2011, 71
[5] Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor
Li, Qi
Xing, Shuaishuai
Chen, Ying
Liao, Qinghong
Xiong, Baichen
He, Siyu
Lu, Weixuan
Liu, Yang
Yang, Hongyu
Li, Qihang
Feng, Feng
Liu, Wenyuan
Chen, Yao
Sun, Haopeng
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (17) : 10030 - 10044
[6] Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development
Robarge, Kirk
Schwarz, Jacob
Blake, Jim
Burkard, Michael
Chan, Jocelyn
Chen, Huifen
Chou, Kang-Jye
Diaz, Dolores
Gaudino, John
Gould, Stephen
Grina, Jonas
Xin Linghu
Liu, Lichuan
Martinson, Matthew
Moreno, David A.
Orr, Christine
Pacheco, Patricia
Qin, Ann
Rasor, Kevin
Ren, Li
Shahidi-Latham, Sheerin
Stults, Jeffrey
Sullivan, Francis
Wang, Weiru
Yin, Peter
Zhou, Aihe
Belvin, Marcia
Merchant, Mark
Moffat, John G.
CANCER RESEARCH, 2014, 74 (19)
[7] Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development
Schwarz, Jacob
Blake, James
Burkard, Michael
Chan, Jocelyn
Chen, Huifen
Chou, Kang-Jye
Diaz, Dolores
Dudley, Danette
Gaudino, John
Gould, Stephen
Grina, Jonas
Hunsaker, Thomas
Liu, Lichuan
Martinson, Matthew
Moreno, David
Orr, Christine
Pacheco, Patricia
Qin, Ann
Rasor, Kevin
Ren, Li
Robarge, Kirk
Shahidi-Latham, Sheerin
Stults, Jeffrey
Sullivan, Francis
Wang, Weiru
Yin, Jianping
Zhou, Aihe
Belvin, Marcia
Merchant, Mark
Moffat, John
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
[8] Discovery of a potent and selective Aurora kinase inhibitor
Oslob, Johan D.
Romanowski, Michael J.
Allen, Darin A.
Baskaran, Subramanian
Bui, Minna
Elling, Robert A.
Flanagan, William M.
Fung, Amy D.
Hanan, Emily J.
Harris, Shannon
Heumann, Stacey A.
Hoch, Ute
Jacobs, Jeffrey W.
Lam, Joni
Lawrence, Chris E.
McDowell, Robert S.
Nannini, Michelle A.
Shen, Wang
Silverman, Jeffrey A.
Sopko, Michelle M.
Tangonan, Bradley T.
Teague, Juli
Yoburn, Josh C.
Yu, Chul H.
Zhong, Min
Zimmerman, Kristin M.
O'Brien, Tom
Lew, Willard
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (17) : 4880 - 4884
[9] Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development
Crawford, James J. y
Johnson, Adam R.
Misner, Dinah L.
Belmont, Lisa D.
Castanedo, Georgette
Choy, Regina
Coraggio, Melis
Doug, Liming
Eigenbrot, Charles
Erickson, Rebecca
Ghilardi, Nico
Hau, Jonathan
Katewa, Arna
Kohli, Pawan Bir
Lee, Wendy
Lubach, Joseph W.
McKenzie, Brent S.
Ortwine, Daniel F.
Schutt, Leah
Tay, Suzanne
Wei, BinQing
Reif, Karin
Liu, Lichuan
Wong, Harvey
Young, Wendy B.
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (06) : 2227 - 2245
[10] Discovery and profiling of a highly potent and selective ERK5 inhibitor: BAY-885
Lemos, Clara
Duy Nguyen
Wortmann, Lars
Boemer, Ulf
Holton, Simon
Lechner, Christian
Prechtl, Stefan
Suelzle, Detlev
Siegel, Franziska
Mumberg, Dominik
Bauser, Marcus
Haegebarth, Andrea
CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →